NEW YORK (GenomeWeb News) – Compugen said today that it will screen peptide candidates for three Pfizer drug targets.

Under the collaboration, Compugen will use its predictive models, algorithms, and computational biology methods to discover and synthesize molecules for the drug maker. Pfizer will pay Compugen for the research, and it will have the right to options for worldwide and exclusive milestones and licenses to develop and commercialize the selected candidates, Compugen said.

Compugen said it expects the studies to take a few months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.